熱門資訊> 正文
scPharmaceuticals获得涵盖SCP-111的多项美国专利申请的许可通知
2025-08-14 22:29
- scPharmaceuticals (NASDAQ:SCPH) has received five notices of allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering their latest furosemide formulation, SCP-111.
- The SCP-111 formulation is the subject of a supplemental NDA expected to be filed by the Company this quarter.
- The five patents, once issued, will join four additional patents owned by the Company that cover the SCP-111 formulation.
More on scPharmaceuticals
- scPharmaceuticals Inc. (SCPH) Q2 2025 Earnings Call Transcript
- scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025
- ScPharmaceuticals anticipates meaningful Q3 nephrology contribution as FUROSCIX shipments rise 45% in Q2 2025
- Seeking Alpha’s Quant Rating on scPharmaceuticals
- Historical earnings data for scPharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
